موقع حكومي رسمي تابع لحكومة المملكة العربية السعودية

الجمعة 12 جمادى الأولى 1448هـ

نسخة تجريبية

روابط المواقع الالكترونية الرسمية السعودية تنتهي بـ gov.sa

جميع روابط المواقع الرسمية التابعة للجهات الحكومية في المملكة العربية السعودية تنتهي بـ .gov.sa

المواقع الرسمية الآمنة تستخدم HTTPS

تحقق من أن الموقع يستخدم بروتوكول HTTPS

مسجل لدى هيئة الحكومة الرقمية برقم :

20250831619

اقتراحات

قائمة الدراسات السريرية المسجلة على الادوية

عرض 191 - 200 من 518

تصفية

عنوان الدراسة	داعم الدراسة	حالة الدراسة	دواء الدراسة	مرحلة الدراسة	رقم بروتوكول الدراسة	موقع الدراسة
An observational study to evaluate the effectiveness, safty and effect on health-related quality of life of treatment in routine practice (PERFORMS)	Novartis	Completed	Fingolimod	4	CFTY720D-MAX-TH-01	King Fahad Medical City (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Jeddah)
An observational, prospective, open-label to assess effectiveness, safety and tolerability of once-yearly treatment with zoledronic acid in osteoporotic patients in a real-world setting (AZURE).	Novartis	Completed	Zoledronic acid	4	CZOL446H-MAX-SA-01	King Fahad University Hospital (Al-Khobar), King Khalid University Hospital (Riyadh)
A Phase 2, Open-label Study to Evaluate the Efficacy and Safety of KB195 in Subjects with a Urea Cycle Disorder with Inadequate Control on Standard of Care	Kaleido Biosciences	Ongoing	KB195	2	K020-218	King Khalid University Hospital (Riyadh), King Abdulaziz Medical City NG (Riyadh)
A two part seamless, open label, multi-center study to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of RO7034067 in infants with type 1 spinal muscular atrophy.	Roche	Terminated	RO7034067	2	BP39056	King Faisal Specialist Hospital and Research Center (Riyadh)
AN OPEN-LABEL, SINGLE-ARM 4-YEAR STUDY TO EVALUATE EFFECTIVENESS AND SAFETY OF OCRELIZUMAB TREATMENT IN PATIENTS WITH PROGRESSIVE MULTIPLE SCLEROSIS	Roche	Terminated	Ocrelizumab	3b	MN39159	King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad Medical City (Riyadh)
A SINGLE-ARM, MULTICENTER PHASE IIIB CLINICAL TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF PROPHYLACTIC EMICIZUMAB IN HEMOPHILIA A PATIENTS WITH INHIBITORS	Roche	Ongoing	Emicizumab	3	MO39129	King Faisal Specialist Hospital and Research Center (Riyadh)
"Tranexamic acid for the treatment of gastrointestinal hemorrhage: aninternational randomized, double-blind, placebo-controlled trial"	Prince Mohammad Bin Abdulaziz Hospital	Completed	Tranexamic acid	3	ISRCTN11225767	Prince Mohammad bin Abdulaziz hospital (Riyadh), King Fahad Medical City (Riyadh)
Randomized, two-way, two- period, single oral dose, open- label, crossover, bioequivalence study to compare Diclofenac Potassium powder for oral solution (50 mg diclofenac potassium) manufactured by Riyadh Pharma versus Catafast® powder for oral solution (50 mg diclofenac potassium) manufactured by Mipharm S.p.A., in healthy subjects under fasting condition.	Saudi Ajal	Completed	DICLOFENAC POTASSIUM	BE	42856	Saudi Ajal
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of Luspatercept (Ace-536) Versus Placebo In Adults Who Require Regular Red Blood Cell Transfusions Due To Beta -Thalassemia The “BELIEVE” Trial	Celgene	Completed	Luspatercept (ACE 536)	3	ACE-536-B-THAL-001	King Khalid University Hospital (Riyadh)
"A Phase IIIb, Single-arm Study to Evaluate the Safety and Immunogenicity ofArabio Meningococcal ACWY Conjugate Vaccine in Healthy Subjects Aged 56Years and Above in Saudi Arabia"	Arabio	Completed	Meningococcal Conjugate Vaccine (MenACWY-CRM) (Aramen)	3b	ARA/001/16	King Khalid University Hospital (Riyadh)